Email this article EVALUATION OF SAFETY OF PROPHYLACTIC USE OF IMMUNOGLOBULINS AGAINST VIRALHEMORRHAGIC FEVERS FROM HORSE BLOOD SERA
- Authors: Khmelev AL1, Borisevich IV1, Chernikova NK1, Makhlay AA1, Mikhaylov VV1, Yakovlev AK1, Podkuyko VN1, Krasnyanskiy VP1, Borisevich SV1, Bondarev VP1, Khmelev AL2, Borisevich IV3, Chernikova NK2, Makhlay AA2, Mikhaylov VV2, Yakovlev AK3, Podkuyko VN2, Krasnyansky VP2, Borisevich SV4, Bondarev VP3
-
Affiliations:
- Branch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - Virological Center, Sergiev Posad, Moscow, Russia
- Tarasevich State Institute of Standardization and Control of Medical Biological Preparations, Moscow, Russia
- Branch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - VirologicalCenter, Sergiev Posad, 2Tarasevich State Institute of Standardization and Control of Medical Biological Preparations,Moscow, Russia
- Issue: Vol 89, No 6 (2012)
- Pages: 103-106
- Section: Articles
- Submitted: 09.06.2023
- Published: 15.12.2012
- URL: https://microbiol.crie.ru/jour/article/view/13771
- ID: 13771
Cite item
Full Text
Abstract
Materials and methods. Clinical-laboratory examination of 24 individuals after intramuscular administration
of heterologous Ebola immunoglobulin was carried out. Anaphylactogenicity of the immunoglobulins was
studied by WD 42-28-8-89 in guinea pigs compared with commercial preparations. Results. Immediate type
reactions were not observed. In individuals with normal anamnesis the number of local reactions was 31%,
general in the form of lung serum disease - 13%. In individuals with unfavorable anamnesis against the
background of desensitization therapy there were almost no reactions; without it local reactions were present
in 50%, mild severity serum lung disease - in 17%, medium - in 33%. Immunoglobulins against especially
dangerous viral agents by anaphylactogenic properties did not differ from commercial heterologous
preparations. Conclusion. Application of specific immunoglobulins from horse blood sera (the main means
of protection from dangerous and especially dangerous exotic viral infections) with compliance by desensitization
principles is relatively safe. Safe level of sensitization properties is characterized by anaphylaxis index
up to 3.7 for guinea pigs.
About the authors
A L Khmelev
I V Borisevich
N K Chernikova
A A Makhlay
V V Mikhaylov
A K Yakovlev
V N Podkuyko
V P Krasnyanskiy
S V Borisevich
V P Bondarev
A L Khmelev
Branch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - Virological Center, Sergiev Posad, Moscow, RussiaBranch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - Virological Center, Sergiev Posad, Moscow, Russia
I V Borisevich
Tarasevich State Institute of Standardization and Control of Medical Biological Preparations, Moscow, RussiaTarasevich State Institute of Standardization and Control of Medical Biological Preparations, Moscow, Russia
N K Chernikova
Branch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - Virological Center, Sergiev Posad, Moscow, RussiaBranch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - Virological Center, Sergiev Posad, Moscow, Russia
A A Makhlay
Branch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - Virological Center, Sergiev Posad, Moscow, RussiaBranch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - Virological Center, Sergiev Posad, Moscow, Russia
V V Mikhaylov
Branch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - Virological Center, Sergiev Posad, Moscow, RussiaBranch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - Virological Center, Sergiev Posad, Moscow, Russia
A K Yakovlev
Tarasevich State Institute of Standardization and Control of Medical Biological Preparations, Moscow, RussiaTarasevich State Institute of Standardization and Control of Medical Biological Preparations, Moscow, Russia
V N Podkuyko
Branch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - Virological Center, Sergiev Posad, Moscow, RussiaBranch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - Virological Center, Sergiev Posad, Moscow, Russia
V P Krasnyansky
Branch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - Virological Center, Sergiev Posad, Moscow, RussiaBranch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - Virological Center, Sergiev Posad, Moscow, Russia
S V Borisevich
Branch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - VirologicalCenter, Sergiev Posad, 2Tarasevich State Institute of Standardization and Control of Medical Biological Preparations,Moscow, RussiaBranch of the 48th Central Research Institute of the Ministry of Defense of the Russian Federation - VirologicalCenter, Sergiev Posad, 2Tarasevich State Institute of Standardization and Control of Medical Biological Preparations,Moscow, Russia
V P Bondarev
Tarasevich State Institute of Standardization and Control of Medical Biological Preparations, Moscow, RussiaTarasevich State Institute of Standardization and Control of Medical Biological Preparations, Moscow, Russia
References
- Анджапаридзе О.Г. Серопрофилактика и серотерапия вирусных инфекций в эксперименте и клинике. М., 1968.
- Борисевич И.В., Краснянский В.П., Михайлов В.В. и др. Разработка и изучение свойств иммуноглобулина против лихорадки Эбола. Вопр. вирусол. 1995, 6: 270-273.
- Борисевич И.В., Маркин В.А., Фирсова И.В. и др. Эпидемиология, профилактика, клиника и лечение геморрагических лихорадок. Вопр. вирусол. 2006, 5: 8-16.
- Борисевич И.В. Потрываева Н.В., Мельников С.А. и др. Получение иммуноглобулина к вирусу Марбург на основе сыворотки лошадей. Вопр. вирусол. 2008, 1: 39-41.
- Краснянский В.П., Градобоев В.Н., Борисевич И.В. и др. Разработка и изучение свойств иммуноглобулина против лихорадки Ласса. Вопр. вирусол. 1997, 2: 71-73.
- Маркин В.А., Михайлов В.В., Краснянский В.П. и др. Разработка принципов экстренной профилактики и лечения лихорадки Эбола. Вопр. вирусол. 1997, 1: 31-34.
- Медуницин Н.В. Вакцинология. М., 2010.
- Онищенко Г.Г., Алешкин В.А., Афанасьев С.С., Поспелова В.В. Иммунобиоло гические препараты и перспективы их применения в инфектологии. М., 2002.
- Синяк К.М., Жарко Т.Р., Вернер О.М. Пособие по медицинским иммунологическим препаратам. Киев, 1992.
- Сумароков А.А., Салмин Л.В. Прививочное дело (Организационно-методические основы) М., 1983.
- Федеральный закон Российской Федерации от 12 апреля 2010 г. №61-ФЗ Об обращении лекарственных средств.
Supplementary files
